BIOGEN INC (IDP.DE) Stock Fundamental Analysis

FRA:IDP • US09062X1037

162.5 EUR
-1.15 (-0.7%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

IDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 77 industry peers in the Biotechnology industry. IDP gets an excellent profitability rating and is at the same time showing great financial health properties. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • IDP had positive earnings in the past year.
  • In the past year IDP had a positive cash flow from operations.
  • IDP had positive earnings in each of the past 5 years.
  • IDP had a positive operating cash flow in each of the past 5 years.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • With an excellent Return On Assets value of 4.39%, IDP belongs to the best of the industry, outperforming 83.12% of the companies in the same industry.
  • IDP has a better Return On Equity (7.08%) than 83.12% of its industry peers.
  • IDP has a Return On Invested Capital of 8.93%. This is amongst the best in the industry. IDP outperforms 89.61% of its industry peers.
  • IDP had an Average Return On Invested Capital over the past 3 years of 8.93%. This is below the industry average of 11.65%.
  • The last Return On Invested Capital (8.93%) for IDP is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • IDP has a better Profit Margin (13.07%) than 83.12% of its industry peers.
  • IDP's Profit Margin has declined in the last couple of years.
  • IDP's Operating Margin of 27.94% is amongst the best of the industry. IDP outperforms 88.31% of its industry peers.
  • IDP's Operating Margin has declined in the last couple of years.
  • The Gross Margin of IDP (75.69%) is better than 66.23% of its industry peers.
  • In the last couple of years the Gross Margin of IDP has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, IDP has more shares outstanding
  • IDP has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IDP has an improved debt to assets ratio.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.36 indicates that IDP is not in any danger for bankruptcy at the moment.
  • IDP has a Altman-Z score of 3.36. This is in the better half of the industry: IDP outperforms 71.43% of its industry peers.
  • The Debt to FCF ratio of IDP is 3.11, which is a good value as it means it would take IDP, 3.11 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.11, IDP belongs to the top of the industry, outperforming 83.12% of the companies in the same industry.
  • IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.34, IDP perfoms like the industry average, outperforming 58.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.36
ROIC/WACC1.09
WACC8.18%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.68, IDP perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
  • A Quick Ratio of 2.03 indicates that IDP has no problem at all paying its short term obligations.
  • IDP has a Quick ratio (2.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • The Revenue has been growing slightly by 2.22% in the past year.
  • The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 3.54% on average per year.
  • The Revenue is expected to decrease by -0.42% on average over the next years.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • IDP is valuated correctly with a Price/Earnings ratio of 12.51.
  • Based on the Price/Earnings ratio, IDP is valued cheaper than 94.81% of the companies in the same industry.
  • IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
  • IDP is valuated correctly with a Price/Forward Earnings ratio of 12.57.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 97.40% of the companies listed in the same industry.
  • IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.02, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.51
Fwd PE 12.57
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 90.91% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 94.81% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.9
EV/EBITDA 8.39
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

FRA:IDP (2/20/2026, 7:00:00 PM)

162.5

-1.15 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap23.85B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.33
Price Target165.61 (1.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)1.49%
PT rev (3m)6.89%
EPS NQ rev (1m)-13.94%
EPS NQ rev (3m)-13.38%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-1.51%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.7%
Valuation
Industry RankSector Rank
PE 12.51
Fwd PE 12.57
P/S 2.84
P/FCF 13.9
P/OCF 12.73
P/B 1.54
P/tB 10.85
EV/EBITDA 8.39
EPS(TTM)12.99
EY7.99%
EPS(NY)12.93
Fwd EY7.96%
FCF(TTM)11.69
FCFY7.2%
OCF(TTM)12.77
OCFY7.86%
SpS57.27
BVpS105.72
TBVpS14.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number175.78
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.36
F-Score4
WACC8.18%
ROIC/WACC1.09
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year11.48%
EBIT Next 3Y4.64%
EBIT Next 5Y1.32%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -0.5% in the next year.